In patients with NAFLD and HCC, upregulation of receptor for advanced glycation end products (RAGE) on CD8+ T cells is revealed which can be a potential biomarker and therapeutic target (120). This evidence concerns the gene CD8A and metabolic dysfunction-associated steatotic liver disease.